Answers are grounded in this paper and cite their sources.
Carbon-coated α-MnO 2 nanowires (C-MnO 2 NWs) were prepared from α-MnO 2 NWs by a two-step sucrose coating and pyrolysis method. This method resulted in the formation of a thin, porous, low mass-percentage amorphous carbon coating (<5 nm, ≤1.2 wt % C) on the nanowire with an increase in single-nanowire electronic conductivity of roughly 5 orders of magnitude (α-MnO 2, 3.2 × 10 –6 S cm –1; C-MnO 2, 0.52 S cm –1 ) and an increase in surface Mn 3+ (average oxidation state: α-MnO 2, 3.88; C-MnO 2, 3.66) while suppressing a phase change to Mn 3 O 4 at high temperature. The enhanced physical and electronic properties of the C-MnO 2 NWs—enriched surface Mn 3+ and high conductivity—are manifested in the electrocatalytic activity toward the oxygen reduction reaction (ORR), where a 13-fold increase in specific activity (α-MnO 2, 0.13 A m –2; C-MnO 2, 1.70 A m –2 ) and 6-fold decrease in charge transfer resistance (α-MnO 2, 6.2 kΩ; C-MnO 2, 0.9 kΩ) were observed relative to the precursor α-MnO 2 NWs. The C-MnO 2 NWs, composed of ∼99 wt % MnO 2 and ∼1 wt % carbon coating, also demonstrated an ORR onset potential within 20 mV of commercial 20% Pt/C and a chronoamperometric current/stability equal to or greater than 20% Pt/C at high overpotential (0.4 V vs RHE) and high temperature (60 °C) with no additional conductive carbon.
No takes yet. Share an insight, caveat, or question.
Vigil et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: